Normal view MARC view ISBD view

Multy-dose dry powder in haler :Advance technology for drug delivery to airways

By: Mehta, P.
Publisher: Mumbai Indian Drug Manufacture's Association - IDMA 2019Edition: Vol.56(11), Nov.Description: 59-62p.Subject(s): PHARMACEUTICSOnline resources: Click here In: Indian drugsSummary: Multi-dose dry powder inhaler (M-DPI) is a unique inhaler device from Teva Pharmaceutical developed for treatment of chronic respiratory diseases. It is a metered-dose dry powder inhaler system designed to appear as a typical pressurized metered-dose inhaler, but its internal geometry is very unique. The formulation of the inhaled corticosteroid and long-acting β2 agonist in M-DPI has been approved for use in the United States (US) [RespiClick®] and European Union (EU) [Spiromax®] as a treatment for asthma and chronic obstructive pulmonary disease (COPD). This M-DPI is easy to handle and does not need coordination between dose actuation and inhalation. The unique design of M-DPI ensures patients receive consistent doses of the drug with each actuation. The present article is a comprehensive account of the M-DPI with special emphasis on its dose metering system, deagglomeration mechanism and clinical outcomes.
Tags from this library: No tags from this library for this title. Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode Item holds
Articles Abstract Database Articles Abstract Database School of Pharmacy
Archieval Section
Not for loan 2020641
Total holds: 0

Multi-dose dry powder inhaler (M-DPI) is a unique inhaler device from Teva Pharmaceutical developed for treatment of chronic respiratory diseases. It is a metered-dose dry powder inhaler system designed to appear as a typical pressurized metered-dose inhaler, but its internal geometry is very unique. The formulation of the inhaled corticosteroid and long-acting β2 agonist in M-DPI has been approved for use in the United States (US) [RespiClick®] and European Union (EU) [Spiromax®] as a treatment for asthma and chronic obstructive pulmonary disease (COPD). This M-DPI is easy to handle and does not need coordination between dose actuation and inhalation. The unique design of M-DPI ensures patients receive consistent doses of the drug with each actuation. The present article is a comprehensive account of the M-DPI with special emphasis on its dose metering system, deagglomeration mechanism and clinical outcomes.

There are no comments for this item.

Log in to your account to post a comment.

Click on an image to view it in the image viewer

Unique Visitors hit counter Total Page Views free counter
Implemented and Maintained by AIKTC-KRRC (Central Library).
For any Suggestions/Query Contact to library or Email: librarian@aiktc.ac.in | Ph:+91 22 27481247
Website/OPAC best viewed in Mozilla Browser in 1366X768 Resolution.

Powered by Koha